Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Completed · Phase 2

Conditions studied: Leukemia, Mast-Cell, Mantle-cell Lymphoma

In brief

To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)

Key facts

Study ID

NCT00186628

Run by

Stanford University

People needed

36

Starts

2005-06-01

Expected to finish

2010-12-01

Last updated by the study team

2017-11-28

Who can join

Age: 18 and older, up to 76. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.